Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

nyo.	rmation and documents given to ASX bec	ome ASX's property and may b	e made public.
Nam	e of entity		ABN/ARSN
_	ma Pharmaceuticals Limited		15 088 417 403
We	(the entity) give ASX the following	ng information.	
Inf	formation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASX	13 September 2012	
	tal of all shares/units be ceptances have been recei	•	
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	4,611,511	494,579

		Before day	Before previous day			Previous day		
5	If buy-back is an on-marked buy-back	Highest \$0.6700	price	paid:	Highest \$0.6600	price	paid:	
		Laurat			Lowest \$0.6525	price	paid:	
		\$0.6250	price	paid:	Highest under \$0.6700	price al rule	llowed 7.33:	

How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back

113,524,262

Date: 19 October 2012

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

(Director/Company secretary)

Print name: SUE MORGAN